eligibility_summary
Eligible: Adults (≥18) with multiple myeloma who will receive at least the first step-up dose of teclistamab. Not eligible: Patients who did not receive study information or who object to data collection, or who received or are initiating teclistamab within an interventional clinical trial.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Teclistamab, a bispecific T‑cell–redirecting monoclonal antibody (IgG4) that targets BCMA (TNFRSF17) on myeloma cells and CD3 on T cells, administered with step-up dosing in clinical use. Mechanism of action: Simultaneous binding to BCMA and CD3 forms an immune synapse, activating T cells to kill BCMA‑expressing malignant plasma cells via cytotoxic granule release and cytokine-mediated T‑cell activation. Cells/pathways targeted: BCMA+ multiple myeloma plasma cells, CD3+ T lymphocytes, engagement of T‑cell receptor/CD3 signaling, immune synapse formation, and effector cytotoxic pathways. Study context: Prospective, multicenter, real‑world observational study in relapsed/refractory multiple myeloma assessing effectiveness (ORR per IMWG) and safety.